Onconetix Inc (ONCO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Onconetix Inc stock (ONCO) is currently trading at $3.03. Onconetix Inc PS ratio (Price-to-Sales) is 1.18. Analyst consensus price target for ONCO is $9.00. WallStSmart rates ONCO as Sell.
- ONCO PE ratio analysis and historical PE chart
- ONCO PS ratio (Price-to-Sales) history and trend
- ONCO intrinsic value — DCF, Graham Number, EPV models
- ONCO stock price prediction 2025 2026 2027 2028 2029 2030
- ONCO fair value vs current price
- ONCO insider transactions and insider buying
- Is ONCO undervalued or overvalued?
- Onconetix Inc financial analysis — revenue, earnings, cash flow
- ONCO Piotroski F-Score and Altman Z-Score
- ONCO analyst price target and Smart Rating
Onconetix Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Onconetix Inc (ONCO) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Onconetix Inc (ONCO) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
Paying $1.18 for every $1 of annual revenue
Supporting Valuation Data
Onconetix Inc (ONCO) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -57.40%, a shrinking business
Very low institutional interest at 1.70%
Micro-cap company with very limited liquidity and high volatility
Onconetix Inc (ONCO) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Price/Sales. Valuation metrics including Price/Sales (1.18), Price/Book (0.06) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -57.40%, which may limit upside. Profitability pressure is visible in Return on Equity at -115.50%, Operating Margin at -422.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -115.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -57.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ONCO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ONCO's Price-to-Sales ratio of 1.18x trades at a 39% premium to its historical average of 0.85x (86th percentile). The current valuation is 0% below its historical high of 1.18x set in Mar 2026, and 91% above its historical low of 0.62x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~0.8x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Onconetix Inc (ONCO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Onconetix Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 815,370 with 57% decline year-over-year.
Key Findings
Debt-to-equity ratio of 0.05 indicates a conservative balance sheet with 836,556 in cash.
Revenue contracted 57% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 3.52, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Onconetix Inc.
Bottom Line
Onconetix Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Onconetix Inc(ONCO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Onconetix Inc. is a pioneering biotechnology firm dedicated to transforming cancer care through the advancement of innovative diagnostic and therapeutic solutions. Leveraging its proprietary technology platform, the company focuses on enhancing early detection and personalized treatment strategies across various malignancies, thereby addressing a critical need in oncology. With a robust pipeline that reflects its commitment to addressing the growing demand for effective cancer therapies, Onconetix is well-positioned to make a significant impact on patient outcomes through its cutting-edge research and development initiatives in the rapidly evolving landscape of cancer treatment.